Effect of Personalized Pharmaceutical Services on the Knowledge, Belief, and Practice of Standardized Treatment for Schizophrenic Patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086195

Enrollment

Unknown

Registered

2024-06-26

Start date

2024-07-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

the control group:Routine pharmaceutical care

the experimental group:Personalized Pharmaceutical Services

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: ? Diagnosis of schizophrenia; ? Age 18-45 years old; ? PANSS positive scale <49 points, or negative scale <49 points; ?SDSS=2 points; ? Have normal understanding and communication skills; ? Identify their own illness and agree to participate in the investigation.

Exclusion criteria

Exclusion criteria: ? Merge with other types of mental system diseases; ? Complication with important organ failure such as heart, lungs, kidneys, and brain; ? The patient and their family members refused to participate in this study.

Design outcomes

Primary

Measure	Time frame
the Knowledge, Belief, and Practice scale score;	—

Secondary

Measure	Time frame
SDSS Scale Rating;PANSS scale score;	—

Countries

China

Contacts

Public ContactXie Haiyan

The Third Hospital of Quzhou

1071201402@qq.com+86 158 6909 8260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026